Bleeding Disorders Treatment Market by Type (Hemophilia A, Hemophilia B, vWD), Drug Class (Plasma Derived Coagulation Factor Concentrates, Recombinant Coagulation Factor Concentrates, Desmopressin, Antibrinolytics, Fibrin Sealant) - Global Forecast to 2021
The global bleeding disorders treatment market is projected to reach USD 15.09 billion by 2021 from USD 10.33 billion in 2016, at a CAGR of 7.9% from 2016 to 2021. The increasing acceptance for prophylaxis treatment among all age groups, rising volume of diagnosed patients, and increasing R&D investments for the development of hemophilia products are driving the global market for bleeding disorders treatment. On the other hand, high costs for bleeding disorder treatment products is a major factor expected to restrain the growth of this market during the forecast period.
The global bleeding disorders treatment market is broadly classified by type and drug class. The hemophilia A segment is projected to register a healthy CAGR during the forecast period. The large number of patients suffering from hemophilia A and rising R&D investment for hemophilia products
The recombinant coagulation factor concentrates segment is expected to witness the highest growth rate in the bleeding disorders treatment market. This growth is attributed to rising R&D activities and increasing focus of pharmaceutical companies on recombinant products resulting in launch of new products.
Geographically, the bleeding disorders treatment market is dominated by North America, followed by Europe. The increasing acceptance of prophylaxis treatment across all age groups is a key factor driving the North American bleeding disorder treatment market.
The key players in the bleeding disorders treatment market are Shire Plc. (earlier Baxalta) (Ireland), Bayer AG (Germany), Biogen Inc. (U.S.), CSL Behring (U.S.), Novo Nordisk (Denmark), Pfizer Inc. (U.S.), and Grifols SA (Spain).
Reasons to Buy the Report:
This report will enable both established firms as well as new entrants/smaller firms to gauge the pulse of the market, which in turn will help these firms garner greater market shares. Firms purchasing the report can use any one or a combination of the below-mentioned five strategies for strengthening their market shares.
The global bleeding disorders treatment market is broadly classified by type and drug class. The hemophilia A segment is projected to register a healthy CAGR during the forecast period. The large number of patients suffering from hemophilia A and rising R&D investment for hemophilia products
The recombinant coagulation factor concentrates segment is expected to witness the highest growth rate in the bleeding disorders treatment market. This growth is attributed to rising R&D activities and increasing focus of pharmaceutical companies on recombinant products resulting in launch of new products.
Geographically, the bleeding disorders treatment market is dominated by North America, followed by Europe. The increasing acceptance of prophylaxis treatment across all age groups is a key factor driving the North American bleeding disorder treatment market.
The key players in the bleeding disorders treatment market are Shire Plc. (earlier Baxalta) (Ireland), Bayer AG (Germany), Biogen Inc. (U.S.), CSL Behring (U.S.), Novo Nordisk (Denmark), Pfizer Inc. (U.S.), and Grifols SA (Spain).
Reasons to Buy the Report:
This report will enable both established firms as well as new entrants/smaller firms to gauge the pulse of the market, which in turn will help these firms garner greater market shares. Firms purchasing the report can use any one or a combination of the below-mentioned five strategies for strengthening their market shares.
- Market Penetration: Comprehensive information on the product portfolios of the top players in the bleeding disorders treatment market. The report analyses the bleeding disorders treatment market by type, drug class, and geography/ region.
- Product Development/Innovation: Detailed insights on the pipeline products, R&D activities, and new product launches in the bleeding disorders treatment market.
- Competitive Assessment: In-depth assessment of the market strategies, geographic and business segments, and product portfolios of the leading players in the bleeding disorders treatment market.
- Market Development: Comprehensive information about emerging markets. This report analyzes the market for various bleeding disorder treatment market products across geographies.
- Market Diversification: Exhaustive information about new products, untapped geographies, recent developments, and investments in the bleeding disorders treatment market.
1 INTRODUCTION
1.1 OBJECTIVES OF THE STUDY
1.2 MARKET DEFINITION
1.3 MARKET SCOPE
1.3.1 MARKETS COVERED
1.3.2 YEARS CONSIDERED FOR THE STUDY
1.4 CURRENCY
1.5 STAKEHOLDERS
1.6 ASSUMPTIONS & LIMITATIONS
2 RESEARCH METHODOLOGY
2.1 INTRODUCTION
2.2 SECONDARY DATA
2.2.1 KEY DATA FROM SECONDARY SOURCES
2.3 PRIMARY DATA
2.3.1 BREAKDOWN OF PRIMARIES
2.3.2 KEY DATA FROM PRIMARY SOURCES
2.3.3 ASSUMPTIONS
2.4 MARKET SIZE ESTIMATION
2.4.1 BOTTOM-UP APPROACH
2.4.2 TOP-DOWN APPROACH
2.5 MARKET BREAKDOWN AND DATA TRIANGULATION
3 EXECUTIVE SUMMARY
3.1 INTRODUCTION
3.2 MARKET DYNAMICS
3.3 MARKET ESTIMATION
4 MARKET DYNAMICS
4.1 MARKET DRIVERS
4.1.1 RISING R&D INVESTMENT FOR DEVELOPMENT OF HEMOPHILIA PRODUCTS
4.1.2 INCREASING PREFERENCE FOR PROPHYLACTIC TREATMENT
4.1.3 INCREASING NUMBER OF DIAGNOSED HEMOPHILIA PATIENTS
4.1.4 INCREASING HEALTHCARE EXPENDITURE
4.2 MARKET RESTRAINTS
4.2.1 HIGH COST OF HEMOPHILIA DRUGS
4.2.2 INSUFFICIENT REIMBURSEMENT
4.3 MARKET OPPORTUNITIES
4.3.1 LOCAL PARTNERSHIPS IN PHARMAEMERGING COUNTRIES
4.3.2 RISING DISPOSABLE INCOME AND IMPROVING HEALTHCARE INFRASTRUCTURE IN DEVELOPING NATIONS
4.3.3 GROWING BIOSIMILAR PRODUCTS MARKET
4.4 MARKET THREATS
4.4.1 HIGH ENTRY BARRIERS CREATED BY LOCAL GOVERNMENT IN CERTAIN COUNTRIES
4.4.2 LOW SWITCH RATE FOR HEMOPHILIA PRODUCTS
4.4.3 HIGH COMPETITION FROM ESTABLISHED PLAYERS
5 GLOBAL BLEEDING DISORDERS TREATMENT MARKET, BY TYPE
5.1 INTRODUCTION
5.2 HEMOPHILIA A
5.3 HEMOPHILIA B
5.4 VON WILLEBRAND DISEASE (vWD)
5.5 OTHERS
6 GLOBAL BLEEDING DISORDERS TREATMENT MARKET, BY DRUG CLASS
6.1 INTRODUCTION
6.2 PLASMA DERIVED COAGULATION FACTOR CONCENTRATES MARKET
6.3 GLOBAL RECOMBINANT COAGULATION FACTOR CONCENTRATES MARKET
6.4 GLOBAL OTHERS BLEEDING DISORDERS TREATMENT MARKET
7 GLOBAL BLEEDING DISORDERS TREATMENT MARKET, BY GEOGRAPHY
7.1 INTRODUCTION
7.2 NORTH AMERICA
7.3 EUROPE
7.4 ASIA-PACIFIC
7.5 REST OF THE WORLD (ROW)
8 COMPETITIVE LANDSCAPE
8.1 MARKET SHARE ANALYSIS, BY KEY PLAYERS
8.2 KEY GROWTH STRATEGIES, 2013 - 2016
8.3 KEY GROWTH STRATEGIES: NEW PRODUCT APPROVAL/LAUNCH, 2013 - 2016
8.4 KEY GROWTH STRATEGIES: AGREEMENTS, 2013 - 2016
8.5 KEY GROWTH STRATEGIES: M&A, 2013 - 2016
8.6 KEY GROWTH STRATEGIES: OTHER STRATEGIES, 2013 - 2016
9 COMPANY PROFILES
9.1 BAXALTA (NOW SHIRE)
9.2 BAYER PHARMACEUTICALS
9.3 NOVO NORDISK A/S
9.4 PFIZER INC.
9.5 BIOGEN IDEC
9.6 CSL BEHRING
9.7 GRIFOLS
9.8 OCTAPHARMA
10 APPENDIX
10.1 KEY INDUSTRY INSIGHTS
10.2 KNOWLEDGE STORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL
10.3 INTRODUCING RT: REAL TIME MARKET INTELLIGENCE
10.4 RELATED REPORTS
1.1 OBJECTIVES OF THE STUDY
1.2 MARKET DEFINITION
1.3 MARKET SCOPE
1.3.1 MARKETS COVERED
1.3.2 YEARS CONSIDERED FOR THE STUDY
1.4 CURRENCY
1.5 STAKEHOLDERS
1.6 ASSUMPTIONS & LIMITATIONS
2 RESEARCH METHODOLOGY
2.1 INTRODUCTION
2.2 SECONDARY DATA
2.2.1 KEY DATA FROM SECONDARY SOURCES
2.3 PRIMARY DATA
2.3.1 BREAKDOWN OF PRIMARIES
2.3.2 KEY DATA FROM PRIMARY SOURCES
2.3.3 ASSUMPTIONS
2.4 MARKET SIZE ESTIMATION
2.4.1 BOTTOM-UP APPROACH
2.4.2 TOP-DOWN APPROACH
2.5 MARKET BREAKDOWN AND DATA TRIANGULATION
3 EXECUTIVE SUMMARY
3.1 INTRODUCTION
3.2 MARKET DYNAMICS
3.3 MARKET ESTIMATION
4 MARKET DYNAMICS
4.1 MARKET DRIVERS
4.1.1 RISING R&D INVESTMENT FOR DEVELOPMENT OF HEMOPHILIA PRODUCTS
4.1.2 INCREASING PREFERENCE FOR PROPHYLACTIC TREATMENT
4.1.3 INCREASING NUMBER OF DIAGNOSED HEMOPHILIA PATIENTS
4.1.4 INCREASING HEALTHCARE EXPENDITURE
4.2 MARKET RESTRAINTS
4.2.1 HIGH COST OF HEMOPHILIA DRUGS
4.2.2 INSUFFICIENT REIMBURSEMENT
4.3 MARKET OPPORTUNITIES
4.3.1 LOCAL PARTNERSHIPS IN PHARMAEMERGING COUNTRIES
4.3.2 RISING DISPOSABLE INCOME AND IMPROVING HEALTHCARE INFRASTRUCTURE IN DEVELOPING NATIONS
4.3.3 GROWING BIOSIMILAR PRODUCTS MARKET
4.4 MARKET THREATS
4.4.1 HIGH ENTRY BARRIERS CREATED BY LOCAL GOVERNMENT IN CERTAIN COUNTRIES
4.4.2 LOW SWITCH RATE FOR HEMOPHILIA PRODUCTS
4.4.3 HIGH COMPETITION FROM ESTABLISHED PLAYERS
5 GLOBAL BLEEDING DISORDERS TREATMENT MARKET, BY TYPE
5.1 INTRODUCTION
5.2 HEMOPHILIA A
5.3 HEMOPHILIA B
5.4 VON WILLEBRAND DISEASE (vWD)
5.5 OTHERS
6 GLOBAL BLEEDING DISORDERS TREATMENT MARKET, BY DRUG CLASS
6.1 INTRODUCTION
6.2 PLASMA DERIVED COAGULATION FACTOR CONCENTRATES MARKET
6.3 GLOBAL RECOMBINANT COAGULATION FACTOR CONCENTRATES MARKET
6.4 GLOBAL OTHERS BLEEDING DISORDERS TREATMENT MARKET
7 GLOBAL BLEEDING DISORDERS TREATMENT MARKET, BY GEOGRAPHY
7.1 INTRODUCTION
7.2 NORTH AMERICA
7.3 EUROPE
7.4 ASIA-PACIFIC
7.5 REST OF THE WORLD (ROW)
8 COMPETITIVE LANDSCAPE
8.1 MARKET SHARE ANALYSIS, BY KEY PLAYERS
8.2 KEY GROWTH STRATEGIES, 2013 - 2016
8.3 KEY GROWTH STRATEGIES: NEW PRODUCT APPROVAL/LAUNCH, 2013 - 2016
8.4 KEY GROWTH STRATEGIES: AGREEMENTS, 2013 - 2016
8.5 KEY GROWTH STRATEGIES: M&A, 2013 - 2016
8.6 KEY GROWTH STRATEGIES: OTHER STRATEGIES, 2013 - 2016
9 COMPANY PROFILES
9.1 BAXALTA (NOW SHIRE)
9.2 BAYER PHARMACEUTICALS
9.3 NOVO NORDISK A/S
9.4 PFIZER INC.
9.5 BIOGEN IDEC
9.6 CSL BEHRING
9.7 GRIFOLS
9.8 OCTAPHARMA
10 APPENDIX
10.1 KEY INDUSTRY INSIGHTS
10.2 KNOWLEDGE STORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL
10.3 INTRODUCING RT: REAL TIME MARKET INTELLIGENCE
10.4 RELATED REPORTS
LIST OF TABLES
Table 1 PIPELINE ANALYSIS (RECENTLY APPROVED)
Table 2 PIPELINE ANALYSIS (TO BE APPROVED)
Table 3 GLOBAL BLEEDING DISORDERS TREATMENT MARKET, BY TYPE, 2014 – 2021 (USD MILLION)
Table 4 HEMOPHILIA A TREATMENT MARKET, BY REGION, 2014 – 2021 (USD MILLION)
Table 5 HEMOPHILIA A TREATMENT MARKET, BY DISEASE MANAGEMENT, 2014 – 2021 (USD MILLION)
Table 6 HEMOPHILIA B TREATMENT MARKET, BY REGION, 2014 – 2021 (USD MILLION)
Table 7 HEMOPHILIA B TREATMENT MARKET, BY DISEASE MANAGEMENT, 2014 – 2021 (USD MILLION)
Table 8 vWD TREATMENT MARKET, BY REGION, 2014 – 2021 (USD MILLION)
Table 9 OTHERS TREATMENT MARKET, BY REGION, 2014 – 2021 (USD MILLION)
Table 10 GLOBAL HEMOPHILIA TREATMENT MARKET, BY DRUG CLASS, 2014 – 2021 (USD MILLION)
Table 11 GLOBAL PLASMA DERIVED COAGULATION FACTOR CONCENTRATE MARKET, BY CLASS, 2014 – 2021 (USD MILLION)
Table 12 GLOBAL PLASMA DERIVED COAGULATION FACTOR CONCENTRATE MARKET, BY GEOGRAPHY, 2014 – 2021 (USD MILLION)
Table 13 GLOBAL RECOMBINANT COAGULATION FACTOR CONCENTRATE MARKET, BY CLASS, 2014 – 2021 (USD MILLION)
Table 14 GLOBAL RECOMBINANT COAGULATION FACTOR CONCENTRATE MARKET, BY GEOGRAPHY, 2014 – 2021 (USD MILLION)
Table 15 OTHER BLEEDING DISORDERS TREATMENT MARKET, BY GEOGRAPHY, 2014 – 2021 (USD MILLION)
Table 16 GLOBAL BLEEDING DISORDERS TREATMENT MARKET SHARE, BY REGION, 2014 - 2021 (USD MILLION)
Table 17 NORTH AMERICA: BLEEDING DISORDERS TREATMENT MARKET SHARE, BY COUNTRY, 2014 - 2021 (USD MILLION)
Table 18 NORTH AMERICA: BLEEDING DISORDERS TREATMENT MARKET SHARE, BY PRODUCT TYPE, 2014 - 2021 (USD MILLION)
Table 19 NORTH AMERICA: BLEEDING DISORDERS TREATMENT MARKET SHARE, BY CLASS, 2014 - 2021 (USD MILLION)
Table 20 NORTH AMERICA: BLEEDING DISORDERS TREATMENT MARKET, BY DISEASE MANAGEMENT, 2014 - 2021 (USD MILLION)
Table 21 EUROPE: BLEEDING DISORDERS TREATMENT MARKET SHARE, BY COUNTRY, 2014 - 2021 (USD MILLION)
Table 22 EUROPE: BLEEDING DISORDERS TREATMENT MARKET SHARE, BY PRODUCT TYPE, 2014 - 2021 (USD MILLION)
Table 23 EUROPE: BLEEDING DISORDERS TREATMENT MARKET SHARE, BY CLASS, 2014 - 2021 (USD MILLION)
Table 24 EUROPE: BLEEDING DISORDERS TREATMENT MARKET, BY DISEASE MANAGEMENT, 2014 - 2021 (USD MILLION)
Table 25 ASIA-PACIFIC: BLEEDING DISORDERS TREATMENT MARKET SHARE, BY COUNTRY, 2014 - 2021 (USD MILLION)
Table 26 ASIA-PACIFIC BLEEDING DISORDERS TREATMENT MARKET SHARE, BY PRODUCT TYPE, 2014 - 2021 (USD MILLION)
Table 27 ASIA-PACIFIC: BLEEDING DISORDERS TREATMENT MARKET SHARE, BY CLASS, 2014 - 2021 (USD MILLION)
Table 28 ASIA-PACIFI:C BLEEDING DISORDERS TREATMENT MARKET, BY DISEASE MANAGEMENT, 2014 - 2021 (USD MILLION)
Table 29 ROW: BLEEDING DISORDERS TREATMENT MARKET SHARE, BY COUNTRY, 2014 - 2021 (USD MILLION)
Table 30 ROW: BLEEDING DISORDERS TREATMENT MARKET SHARE, BY PRODUCT TYPE, 2014 - 2021 (USD MILLION)
Table 31 ROW: BLEEDING DISORDERS TREATMENT MARKET SHARE, BY CLASS, 2014 - 2021 (USD MILLION)
Table 32 ROW: BLEEDING DISORDERS TREATMENT MARKET, BY DISEASE MANAGEMENT, 2014 - 2021 (USD MILLION)
Table 33 NEW PRODUCT APPROVAL/LAUNCH, 2013 - 2016
Table 34 AGREEMENTS, 2013 - 2016
Table 35 M&A, 2013 - 2016
Table 36 OTHER STATEGIES, 2013 – 2016
Table 1 PIPELINE ANALYSIS (RECENTLY APPROVED)
Table 2 PIPELINE ANALYSIS (TO BE APPROVED)
Table 3 GLOBAL BLEEDING DISORDERS TREATMENT MARKET, BY TYPE, 2014 – 2021 (USD MILLION)
Table 4 HEMOPHILIA A TREATMENT MARKET, BY REGION, 2014 – 2021 (USD MILLION)
Table 5 HEMOPHILIA A TREATMENT MARKET, BY DISEASE MANAGEMENT, 2014 – 2021 (USD MILLION)
Table 6 HEMOPHILIA B TREATMENT MARKET, BY REGION, 2014 – 2021 (USD MILLION)
Table 7 HEMOPHILIA B TREATMENT MARKET, BY DISEASE MANAGEMENT, 2014 – 2021 (USD MILLION)
Table 8 vWD TREATMENT MARKET, BY REGION, 2014 – 2021 (USD MILLION)
Table 9 OTHERS TREATMENT MARKET, BY REGION, 2014 – 2021 (USD MILLION)
Table 10 GLOBAL HEMOPHILIA TREATMENT MARKET, BY DRUG CLASS, 2014 – 2021 (USD MILLION)
Table 11 GLOBAL PLASMA DERIVED COAGULATION FACTOR CONCENTRATE MARKET, BY CLASS, 2014 – 2021 (USD MILLION)
Table 12 GLOBAL PLASMA DERIVED COAGULATION FACTOR CONCENTRATE MARKET, BY GEOGRAPHY, 2014 – 2021 (USD MILLION)
Table 13 GLOBAL RECOMBINANT COAGULATION FACTOR CONCENTRATE MARKET, BY CLASS, 2014 – 2021 (USD MILLION)
Table 14 GLOBAL RECOMBINANT COAGULATION FACTOR CONCENTRATE MARKET, BY GEOGRAPHY, 2014 – 2021 (USD MILLION)
Table 15 OTHER BLEEDING DISORDERS TREATMENT MARKET, BY GEOGRAPHY, 2014 – 2021 (USD MILLION)
Table 16 GLOBAL BLEEDING DISORDERS TREATMENT MARKET SHARE, BY REGION, 2014 - 2021 (USD MILLION)
Table 17 NORTH AMERICA: BLEEDING DISORDERS TREATMENT MARKET SHARE, BY COUNTRY, 2014 - 2021 (USD MILLION)
Table 18 NORTH AMERICA: BLEEDING DISORDERS TREATMENT MARKET SHARE, BY PRODUCT TYPE, 2014 - 2021 (USD MILLION)
Table 19 NORTH AMERICA: BLEEDING DISORDERS TREATMENT MARKET SHARE, BY CLASS, 2014 - 2021 (USD MILLION)
Table 20 NORTH AMERICA: BLEEDING DISORDERS TREATMENT MARKET, BY DISEASE MANAGEMENT, 2014 - 2021 (USD MILLION)
Table 21 EUROPE: BLEEDING DISORDERS TREATMENT MARKET SHARE, BY COUNTRY, 2014 - 2021 (USD MILLION)
Table 22 EUROPE: BLEEDING DISORDERS TREATMENT MARKET SHARE, BY PRODUCT TYPE, 2014 - 2021 (USD MILLION)
Table 23 EUROPE: BLEEDING DISORDERS TREATMENT MARKET SHARE, BY CLASS, 2014 - 2021 (USD MILLION)
Table 24 EUROPE: BLEEDING DISORDERS TREATMENT MARKET, BY DISEASE MANAGEMENT, 2014 - 2021 (USD MILLION)
Table 25 ASIA-PACIFIC: BLEEDING DISORDERS TREATMENT MARKET SHARE, BY COUNTRY, 2014 - 2021 (USD MILLION)
Table 26 ASIA-PACIFIC BLEEDING DISORDERS TREATMENT MARKET SHARE, BY PRODUCT TYPE, 2014 - 2021 (USD MILLION)
Table 27 ASIA-PACIFIC: BLEEDING DISORDERS TREATMENT MARKET SHARE, BY CLASS, 2014 - 2021 (USD MILLION)
Table 28 ASIA-PACIFI:C BLEEDING DISORDERS TREATMENT MARKET, BY DISEASE MANAGEMENT, 2014 - 2021 (USD MILLION)
Table 29 ROW: BLEEDING DISORDERS TREATMENT MARKET SHARE, BY COUNTRY, 2014 - 2021 (USD MILLION)
Table 30 ROW: BLEEDING DISORDERS TREATMENT MARKET SHARE, BY PRODUCT TYPE, 2014 - 2021 (USD MILLION)
Table 31 ROW: BLEEDING DISORDERS TREATMENT MARKET SHARE, BY CLASS, 2014 - 2021 (USD MILLION)
Table 32 ROW: BLEEDING DISORDERS TREATMENT MARKET, BY DISEASE MANAGEMENT, 2014 - 2021 (USD MILLION)
Table 33 NEW PRODUCT APPROVAL/LAUNCH, 2013 - 2016
Table 34 AGREEMENTS, 2013 - 2016
Table 35 M&A, 2013 - 2016
Table 36 OTHER STATEGIES, 2013 – 2016
LIST OF FIGURES
Fig 1 GLOBAL HEMOPHILIA TREATMENT MARKET SEGMENTATION
Fig 2 RESEARCH DESIGN
Fig 3 BREAKDOWN OF SUPPLY-SIDE PRIMARY INTERVIEWS: BY COMPANY TYPE, DESIGNATION, REGION
Fig 4 MARKET SIZE ESTIMATION DIAGRAM
Fig 5 MARKET DATA TRIANGULATION METHODOLOGY
Fig 6 COMPARATIVE ANALYSIS, GLOBAL MARKET BY TYPE 2015 VS 2021
Fig 7 COMPARATIVE ANALYSIS, GLOBAL MARKET BY DRUG CLASS 2015 VS 2021
Fig 8 GLOBAL SNAPSHOT: BLEEDING DISORDERS TREATMENT MARKET SCENARIO, 2015
Fig 9 IMPACT ANALYSIS: DRIVERS, RESTRAINTS, OPPORTUNITIES & CHALLENGES
Fig 10 BLEEDING DISORDERS TREATMENT MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES & CHALLENGES
Fig 11 MARKET ATTRACTIVENESS, BY TYPE
Fig 12 MARKET ATTRACTIVENESS, BY DRUG CLASS
Fig 13 GLOBAL BLEEDING DISORDERS TREATMENT MARKET SHARE, BY REGION, 2015 (USD MILLION)
Fig 14 GLOBAL BLEEDING DISORDERS TREATMENT MARKET SCENARIO, BY GEOGRAPHY, 2015
Fig 15 NORTH AMERICA: BLEEDING DISORDERS TREATMENT MARKET OVERVIEW
Fig 16 EUROPE: BLEEDING DISORDERS TREATMENT MARKET OVERVIEW
Fig 17 ASIA-PACIFIC: BLEEDING DISORDERS TREATMENT MARKET OVERVIEW
Fig 18 ROW: BLEEDING DISORDERS TREATMENT MARKET OVERVIEW
Fig 19 MARKET SHARE ANALYSIS, BY KEY PLAYERS, 2015 (%)
Fig 20 COMPETITIVE LANDSCAPE: KEY DEVELOPMENTS
Fig 1 GLOBAL HEMOPHILIA TREATMENT MARKET SEGMENTATION
Fig 2 RESEARCH DESIGN
Fig 3 BREAKDOWN OF SUPPLY-SIDE PRIMARY INTERVIEWS: BY COMPANY TYPE, DESIGNATION, REGION
Fig 4 MARKET SIZE ESTIMATION DIAGRAM
Fig 5 MARKET DATA TRIANGULATION METHODOLOGY
Fig 6 COMPARATIVE ANALYSIS, GLOBAL MARKET BY TYPE 2015 VS 2021
Fig 7 COMPARATIVE ANALYSIS, GLOBAL MARKET BY DRUG CLASS 2015 VS 2021
Fig 8 GLOBAL SNAPSHOT: BLEEDING DISORDERS TREATMENT MARKET SCENARIO, 2015
Fig 9 IMPACT ANALYSIS: DRIVERS, RESTRAINTS, OPPORTUNITIES & CHALLENGES
Fig 10 BLEEDING DISORDERS TREATMENT MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES & CHALLENGES
Fig 11 MARKET ATTRACTIVENESS, BY TYPE
Fig 12 MARKET ATTRACTIVENESS, BY DRUG CLASS
Fig 13 GLOBAL BLEEDING DISORDERS TREATMENT MARKET SHARE, BY REGION, 2015 (USD MILLION)
Fig 14 GLOBAL BLEEDING DISORDERS TREATMENT MARKET SCENARIO, BY GEOGRAPHY, 2015
Fig 15 NORTH AMERICA: BLEEDING DISORDERS TREATMENT MARKET OVERVIEW
Fig 16 EUROPE: BLEEDING DISORDERS TREATMENT MARKET OVERVIEW
Fig 17 ASIA-PACIFIC: BLEEDING DISORDERS TREATMENT MARKET OVERVIEW
Fig 18 ROW: BLEEDING DISORDERS TREATMENT MARKET OVERVIEW
Fig 19 MARKET SHARE ANALYSIS, BY KEY PLAYERS, 2015 (%)
Fig 20 COMPETITIVE LANDSCAPE: KEY DEVELOPMENTS
